Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 24, 2026
DICER1-mutated renal neoplasia: A series of 5 cases demonstrating the spectrum of cystic nephroma, Wilms tumor, and anaplastic sarcoma.
Journal: Human pathology
Published: February 10, 2026
A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma.
Journal: British journal of cancer
Published: January 14, 2026
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 20, 2025
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial.
Journal: The Lancet. Oncology
Published: June 17, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 23, 2025
Cardiac benign metastatic leiomyoma- a comprehensive review.
Journal: Cardio-oncology (London, England)
Published: October 28, 2024
Molecular markers of proliferation, DNA repair, and immune infiltration defines high-risk subset of resectable retroperitoneal sarcomas.
Journal: Surgical oncology
Published: June 20, 2024
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.
Journal: Lancet (London, England)
Published: May 01, 2024
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 29, 2024
Last Updated: 09/26/2026